|Product Type||Primary Antibodies|
The antibody (T2H5) reacts with at least two forms of Tenascin (apparent MW between 210 and 300 kDa), an. During embryonic development Tenascin appears to play a regulatory role in epithelial differentiation. In many mature tissues Tenascin disappears, but reappears in tissue regeneration and repair, as well as in neoplasia. Tenascin expression has been noted in a variety of epithelial neoplasms, including skin-, prostate-, breast- and colon cancer. Tenascin is a high molecular ECM glycoprotein (calculated MW 240 kDa), which contains hexamere repeat-rich single chains. It contains EGF-, Fibronectin III- and Fibronectin-similar structures. During organogenesis it is exprimed temporarily by many organs. During adulthood expression of the protein it reappears only in regeneration, wound healing and in stroma of various tumours. Probably it has an anti-adhesive function, which plays a role during tumour spreading. Tenascin is found in the central and peripheral nerve system, in smooth muscle, tendon and hyper-proliferative skin. Human Tenascin, extracellular matrix protein.
Immunogen: Purified Tenascin derived from mammary tumour cells
Purified antibody in phosphate buffer, BSA and 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art .No. PU002.
Purification Method: Purified antibody in phosphate buffer, BSA and 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art .No. PU002.
Concentration: 50 µg/ml
Secondary Reagents: We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art.-No. AE005).
Species Reactivity: Human
Incubation Time: 60 min at RT
Working Concentration: (liquid conc.) 1:10-1:50
Pre-Treatment: Unmasking methods for paraffin sections are not established
Positive Control: Colon carcinoma, abortive tissue, hyperproliferative skin, tonsil
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.
1. Le Poole IC, van den Wijngaard RM, Westerhof W, Das PK. Tenascin is overexpressed in vitiligo lesional skin and inhibits melanocyte adhesion. Br J Dermatol. 1997 Aug;137(2):171-8. 2. Le Poole IC, van den Wijngaard RM, Westerhof W, Das PK. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol. 1996 Apr;148(4):1219-28. 3. Rulo HF, van Vlijmen-Willems IM, Schalkwijk J, Verstraeten AA, van de Kerkhof PC. Normal human skin demonstrates marked site-variation of tenascin expression, not correlated to epidermal proliferation (Ki-67 binding).J Dermatol Sci. 1993 Feb;5(1):54-7. 4. Verstraeten AA, Mackie EJ, Hageman PC, Hilgers J, Schol DJ, De Jongh GJ, Schalkwijk J. Tenascin expression in basal cell carcinoma. Br J Dermatol. 1992 Dec;127(6):571-4. 5.. Müller S., Neureiter D., Stolte M. et al. (1991) Virchows Arch. 438; 435-441.
Database Name: UniProt
Accession number: P24821
Safety Datasheet(s) for this product:
/wp-content/uploads/SDS/Antibody SDS with Sodium Azide Noridic-MUbio.pdf